19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of patients with a post‑transplant lymphoproliferative disorder caused by the Epstein‑Barr virus.

This is because Pierre Fabre did not provide an evidence submission.

Read NICE technology appraisal